Disease · MONDO_0006468

thyroid gland undifferentiated (anaplastic) carcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. thyroid gland undifferentiated (anaplastic) carcinoma. Diseases, record MONDO_0006468. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006468

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: thyroid gland undifferentiated (anaplastic) carcinoma; Open Targets
Open Targets ID: MONDO_0006468; Open Targets
Other names: Dedifferentiated thyroid gland carcinoma, anaplastic carcinoma of the thyroid, anaplastic carcinoma of the thyroid gland, anaplastic carcinoma of thyroid, anaplastic carcinoma of thyroid gland, anaplastic thyroid cancer, anaplastic thyroid carcinoma, anaplastic thyroid gland carcinoma, metaplastic thyroid gland carcinoma, pleomorphic thyroid gland carcinoma, sarcomatoid thyroid gland carcinoma, thyroid gland carcinosarcoma, thyroid gland undifferentiated carcinoma, undifferentiated (anaplastic) thyroid gland cancer, undifferentiated (anaplastic) thyroid gland carcinoma, undifferentiated carcinoma of the thyroid, undifferentiated carcinoma of the thyroid gland, undifferentiated carcinoma of thyroid, undifferentiated carcinoma of thyroid gland, undifferentiated thyroid carcinoma, undifferentiated thyroid gland carcinoma, undifferentiated thyroid tumor, undifferentiated thyroid tumour; Open Targets
Disease Ontology: DOID:0080522; Disease Ontology
MeSH: D065646; MeSH
NCI Thesaurus: C3878; NCI Thesaurus
Orphanet: ORPHA:142; Orphanet
Highest stage of its drugs: Phase 3, for 3 of its 68 drugs, from ClinicalTrials.gov; Open Targets

Drugs68

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PACLITAXEL	CHEMBL428647	Small molecule	Phase 3	ClinicalTrials.gov	8	8	8	Drugs and targets
CARBOPLATIN	CHEMBL1351	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
FOSBRETABULIN	CHEMBL1206232	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
DABRAFENIB	CHEMBL2028663	Small molecule	Phase 2	ClinicalTrials.gov	7	7	7	Drugs and targets
TRAMETINIB	CHEMBL2103875	Small molecule	Phase 2	ClinicalTrials.gov	7	7	7	Drugs and targets
PEMBROLIZUMAB	CHEMBL3137343	Antibody	Phase 2	ClinicalTrials.gov	6	6	6	Drugs and targets
LENVATINIB	CHEMBL1289601	Small molecule	Phase 2	ClinicalTrials.gov	5	5	5	Drugs and targets
CEMIPLIMAB	CHEMBL4297723	Antibody	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
SORAFENIB	CHEMBL1336	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
BEVACIZUMAB	CHEMBL1201583	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 68

See all 68 drugs

Targets97

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
KDR	Vascular endothelial growth factor receptor	10	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3791	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	8	Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2324	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	7	Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2321	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	6	Stem cell growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3815	Drugs and targets
PDCD1	Programmed cell death protein 1	6	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 2	https://conductscience.org/library/genes/5133	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor	6	Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/5159	Drugs and targets
RET	Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET	5	Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET inhibitor; Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET inhibitor; Tyrosine-protein kinase receptor RET inhibitor	Phase 2	https://conductscience.org/library/genes/5979	Drugs and targets
TUBA1A	Tubulin	4	Tubulin disrupting agent; Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	4	Tubulin disrupting agent; Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	4	Tubulin disrupting agent; Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/84790	Drugs and targets

1 to 10 of 97

See all 97 targets

Trials52

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02404441	Phase I/II Study of PDR001 in Patients With Advanced Malignancies	Phase 1/2	319	2021-09-29	Melanoma, Non-small Sell Lung Cancer (NSCLC), Triple Negative Breast Cancer, Anaplastic Thyroid Cancer, Other Solid Tumors	SPARTALIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT03733990	A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS)	Phase 1/2	216	2025-04-02	Cancer	BEXMARILIMAB	Its record names the disease	ClinicalTrials.gov
NCT01524978	A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers	Phase 2	208	2017-11-20	Multiple Myeloma, Neoplasms	CETUXIMAB, VEMURAFENIB	Its record names the disease	ClinicalTrials.gov
NCT02034110	Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers	Phase 2	206	2023-08-21	Cancer	DABRAFENIB, TRAMETINIB	Its record names the disease	ClinicalTrials.gov
NCT00625846	Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer	Phase 2	152	2020-02-26	Recurrent Thyroid Gland Carcinoma, Stage III Differentiated Thyroid Gland Carcinoma AJCC v7, Stage III Thyroid Gland Medullary Carcinoma AJCC v7, Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7, Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v7, Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7, Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7, Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v7, Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7, Stage IVC Differentiated Thyroid Gland Carcinoma AJCC v7, Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v7, Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7, Thyroid Gland Anaplastic Carcinoma	PAZOPANIB HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT01236547	Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer	Phase 2	123	2021-05-14	Thyroid Gland Anaplastic Carcinoma	PACLITAXEL, PAZOPANIB HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT00507429	Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer	Phase 2/3	80	2014-06-09	Anaplastic Thyroid Cancer	CARBOPLATIN, FOSBRETABULIN, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT03246958	Nivolumab Plus Ipilimumab in Thyroid Cancer	Phase 2	53	2024-05-21	Thyroid Cancer	IPILIMUMAB, NIVOLUMAB	Its record names the disease	ClinicalTrials.gov
NCT01728623	A Study of E7080 in Subjects With Advanced Thyroid Cancer	Phase 2	51	2020-08-14	Thyroid Cancer	LENVATINIB, LENVATINIB MESYLATE	Its record names the disease	ClinicalTrials.gov
NCT02657369	A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)	Phase 2	34	2019-10-15	Thyroid Carcinoma, Anaplastic	LENVATINIB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 52

See all 52 trials

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Cohort 3b: Colorectal Cancer - Vemurafenib + Cetuximab vs Pooled Arm - Vemurafenib: serious adverse events	11 of 27	91 of 181	208	NCT01524978	Trial comparisons
Arm 1, Active: CA4P + Carboplatin + Paclitaxel vs Arm 2, Comparator: Carboplatin + Paclitaxel: serious adverse events	21 of 51	5 of 24	75	NCT00507429	Trial comparisons

Papers from its trials36

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
28301826	RESULT	1	PubMed
20189981	RESULT	1	PubMed
19265494	RESULT	1	PubMed
42673705	DERIVED	1	PubMed
40304938	DERIVED	1	PubMed
39446377	DERIVED	1	PubMed
39446365	DERIVED	1	PubMed
38056464	DERIVED	1	PubMed
37934000	DERIVED	2	PubMed
37816266	DERIVED	2	PubMed

1 to 10 of 36

See all 36 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006468

GET https://conductscience.org/api/diseases/v1/MONDO_0006468/drugs?page=2

API reference For AI assistants